Kenneth Shain

Department of Cancer Imaging and Metabolism, H. Lee Moffitt Cancer Center and Research Institute

Affiliated withH. Lee Moffitt Cancer Center and Research Institute

Research Area

Biography

Kenneth Shain has not added Biography.
If you are Kenneth Shain and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 29	2015

Other Publications

Article	Year
Multiple Myeloma: New Insights and Therapeutic Approaches. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program\| PubMed ID: 11701540	2000
Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hemat... Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 11859150	2002
Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer research\| PubMed ID: 12907606	2003
Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer research\| PubMed ID: 14633719	2003
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature medicine\| PubMed ID: 14702634	2004
Targeting the bone marrow microenvironment in hematologic malignancies. Seminars in hematology\| PubMed ID: 15190509	2004
Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 15778348	2005
Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 18209050	2008
Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer research\| PubMed ID: 19155309	2009
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer research\| PubMed ID: 19934314	2009
Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert review of hematology\| PubMed ID: 21082957	2009
Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clinical lymphoma, myeloma & leukemia\| PubMed ID: 21813352	2011
Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma. Molecular & cellular proteomics : MCP\| PubMed ID: 21846842	2011
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. British journal of haematology\| PubMed ID: 22449149	2012
Metastatic myeloma? Blood\| PubMed ID: 22700691	2012
Stemness of B-cell progenitors in multiple myeloma bone marrow. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22988056	2012
Sequence of novel agents in multiple myeloma: an instrumental variable analysis. Leukemia research\| PubMed ID: 23809054	2013
Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma. American journal of hematology\| PubMed ID: 24030918	2014
A preclinical assay for chemosensitivity in multiple myeloma. Cancer research\| PubMed ID: 24310398	2014
An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma. European journal of haematology\| PubMed ID: 25600676	2015
Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. Methods (San Diego, Calif.)\| PubMed ID: 25782629	2015
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Cancer\| PubMed ID: 26149422	2015